International Journal of Molecular Medicine · 2008 · 362 citations · 16 references
Life SciencesEndocrinologyMolecular BiologyGene ExpressionMetabolismSignal TransductionFatty Acid MetabolismFatty Acid SynthesisHepatic PathophysiologyLipid MetabolismLiver DiseaseMetabolic Liver DiseaseFatty AcidsForkhead Box ProteinsInsulin Receptor Substrate ProteinsInsulin Regulation Of Fatty Acid OxidationIrs ProteinsSterol Regulatory Element-binding Protein RegulationSterol Regulatory Element-binding ProteinsTranscriptional Control Of Fatty Acid Oxidation
Nonalcoholic fatty liver disease (NAFLD) is a common liver disease whose prevalence has increased markedly. We reported previously that fatty acid synthesis was enhanced in NAFLD with the accumulation of fatty acids. To clarify the disorder, we evaluated the expression of genes regulating fatty acid synthesis by real-time PCR using samples from NAFLD (n=22) and normal liver (control; n=10). A major regulator of fatty acids synthesis is sterol regulatory element-binding protein-1c (SREBP-1c). Its expression was significantly higher in NAFLD, nearly 5-fold greater than the controls. SREBP-1c is positively regulated by insulin signaling pathways, including insulin receptor substrate (IRS)-1 and -2. In NAFLD, IRS-1 expression was enhanced and correlated positively with SREBP-1c expression. In contrast, IRS-2 expression decreased by 50% and was not correlated with SREBP-1c. Forkhead box protein A2 (Foxa2) is a positive regulator of fatty acid oxidation and is itself negatively regulated by IRSs. Foxa2 expression increased in NAFLD and showed a negative correlation with IRS-2, but not with IRS-1, expression. It is known that SREBP-1c is negatively regulated by AMP-activated protein kinase (AMPK) but expression levels of AMPK in NAFLD were almost equal to those of the controls. These data indicate that, in NAFLD, insulin signaling via IRS-1 causes the up-regulation of SREBP1-c, leading to the increased synthesis of fatty acids by the hepatocytes; negative feedback regulation via AMPK does not occur and the activation of Foxa2, following a decrease of IRS-2, up-regulates fatty acid oxidation.
16
Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆
Christi A Matteoni, Zobair M. Younossi, T GRAMLICH et al. · Gastroenterology · 1999 · 3.4K citations · Full text
Nonalcoholic Fatty Liver Disease
Giulio Marchesini, Mara Brizi, Giampaolo Bianchi et al. · Diabetes · 2001 · 2.6K citations · Full text
Medicine, Pathology, Hepatology +11